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Aims Antecedent blood pressure (BP) may contribute to cardiovascular disease (CVD) independent of current BP. Blood
pressure is associated with left ventricular mass index (LVMI) which independently predicts CVD. We investigated the
relationship between midlife BP from age 36 to 64 and LVMI at 60–64 years.
Methods
and results
A total of 1653 participants in the British 1946 Birth Cohort underwent BP measurement and echocardiography aged
60–64. Blood pressure had previously been measured at 36, 43, and 53 years. We investigated associations between
BP at each age and rate of change in systolic blood pressure (SBP) between 36–43, 43–53, and 53–60/64 years on
LVMI at 60–64 years. Blood pressure from 36 years was positively associated with LVMI. Association with SBP at 53
years was independent of SBP at 60–64 years and other potential confounders (fully adjusted b at 53 years¼ 0.19 g/m2;
95% CI: 0.11, 0.27; P, 0.001). Faster rates of increase in SBP from 43 to 53 years and 53 to 60/64 years were associated
with increased LVMI. Similar relationships were seen for diastolic, pulse, and mean pressure. Rate of increase in SBP
between 43–53 years was associated with largest change in LVMI (b at 43–53 years ¼ 3.12 g/m2; 95% CI: 1.53, 4.72;
P, 0.001). People on antihypertensive medication (43 years onwards) had greater LVMI even after adjustment for
current BP (b at 43 years ¼ 12.36 g/m2; 95% CI: 3.19, 21.53; P ¼ 0.008).
Conclusion Higher BP in midlife and rapid rise of SBP in 5th decade is associated with higher LVMI in later life, independent of current
BP. People with treated hypertension have higher LVMI than untreated individuals, even accounting for their higher BP.
Our findings emphasize importance of midlife BP as risk factor for future CVD.
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Introduction
Highbloodpressure (BP) is a key risk factor forcardiovasculardisease
(CVD)1 and is associated with increased left ventricular (LV) mass
(LVM)2 and left ventricular hypertrophy (LVH) and remodelling.3
LVH is widely used as a measure of target organ damage in hyperten-
sion and increased LVM and LVH are associated with CVD independ-
ent of current BP.2
Exposure to elevated BP over the life course increases the risk of
CVD.4 There is evidence that earlier development of hypertension,5
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elevated BP in early adulthood6 or antecedent elevated BP7 confer
increased risk. This might reflect the relative stability (tracking) of
BP across life; the cumulative burden of lifetime exposure to high
BP; or vulnerability to the effects of high BP at particular periods in
the life course, i.e. sensitive periods. The extent to which the influ-
ence of long-term elevated BP can be reversed by treatment or the
extent to which long-term treatment prevents increases in LVM
has been little studied outside the context of clinical trials, although
several trials have demonstrated that antihypertensive treatment
(HTT) causes regression of LVM in the short term.8
We studied the nationally representative 1946 British birth cohort
[the Medical Research Council National Survey of Health and Devel-
opment (MRC NSHD)], to determine the relationship between lon-
gitudinal changes in BP over a 28-year period (aged 36 to 60–64) and
LVM at age 60–64 years and also assessed the impact of HTT in the
same individuals over the same period.
Methods
Participants
The MRC NSHD is a prospective birth cohort study of singleton births
that occurred in 1 week of March 1946 in England, Scotland, and Wales
(5362 births; 2547 women, 2815 men). The parents of the cohort
members were married with equal numbers of fathers engaged in manual
and non-manual work. Follow-up included over 20 contacts with the
whole cohort between birth and the most recent data collection when
the participants were between 60 and 64 years of age. The study complies
with the Declaration of Helsinki, the research protocol was approved by
the local ethics committee and all participants gave informed consent.
Survey members had been interviewed in their own homes by trained
research nurses at ages 36, 43, and 53 years.9 Between October 2006 and
February 2011 (at 60–64 years), 2856 eligible study members (those
known to be alive and with a known address in England, Scotland, or
Wales) were invited to complete a postal questionnaire and attend an
assessment at one of six Clinical Research Facilities (CRF). Invitations
were not sent to those who had died (n ¼ 778), were living abroad
(n ¼ 570), had previously withdrawn from the study (n ¼ 594), or had
been lost to follow-up (n ¼ 564). Those who declined the clinic visit
were offered a home examination by a trained nurse. Of those invited,
2229 (78%) responded: 1690 (59.1%) attended a CRF and 539 (18.9%)
had a home visit.
Clinic assessment
Height and weight were measured at the CRF and body mass index (BMI)
calculated. Sitting brachial BP was measured in the upper right arm as the
average of two measures with an appropriately sized cuff after 5 min of
rest. At 36 and 43 years a Hawksley Random Zero sphygmomanometer
was used and an Omron HEM-705 was used at 53 and 60–64 years. Mea-
surements from the Random Zero sphygmomanometer were adjusted
using published conversion equations to achieve compatibility with
later measurements.10 Mean arterial pressure (MAP) was calculated as
diastolic BP (DBP) + 0.33*pulse pressure (PP). Fasting bloods were
also drawn for analysis.
Echocardiographic studies
Of the 1690 participants who attended a clinic, 1653 (798 men and 855
women) underwent echocardiography performed by a trained, experi-
enced sonographer according to a strict protocol using GE Vivid I
machines and 1480 had analysable images (89%). We carried out
sensitivity analyses excluding those with a history of prior myocardial in-
farction. As there were no significant change on exclusion (Supplemen-
tary material online, Table S10), only those with unanalysable images
were excluded from the analyses. Echocardiographic images were
obtained from parasternal long axis and short axis, apical 5-, 4-, 3-,
2-chamber and aortic views along with conventional and tissue
Doppler in the 4-chamber view. Image optimization was carried out if
required using second harmonic imaging. Image analysis was carried
out by AKG along with two experienced echocardiographers masked
to patient identity using GE EchoPac software (GE Connecticut, USA).
Wall and chamber measures were made in a single core laboratory,
LVM was indexed (LVMI) to body surface area (BSA),11 alternative
indexation (height1.7 and height2.7)12,13 was also performed to check
robustness of findings in the setting of overweight or obesity. Calculation
of variables and definition of LVH and LV remodelling was performed
according to ASE/EAE guidelines.11 Quality assurance of echocardiog-
raphy was performed throughout the study and blind duplicate reading
reproducibility studies were carried out on a sample of studies (equal
numbers of men and women and with varying image quality) to establish
inter- and intrareader variability with excellent reproducibility (intraclass
correlation coefficients . 0.8 for all measurements).
Medication, antihypertensive treatment,
and diabetes status
Medication usewasrecorded andclassified according to the International
Classification of Diseases and related Health Problems classification.9,14
Type 2 diabetes mellitus (T2DM) was diagnosed based on self-report or
clinic blood tests.
Statistical analysis
Regression models were used to investigate the association between BP
[systolic blood pressure (SBP), DBP, PP, and MAP] at each of the 4 ages at
which it was measured and LVMI at 60–64 years, routinely with pre-
specified covariable adjustment for sex, age at CRF visit and CRF
attended. All analyses were carried out with SBP, DBP, PP, or MAP as
the respective measure of BP in the model. Interactions between each
BP measure and sex were tested, but no significant interactions were
found for any of the outcomes presented and data for men and women
were pooled. Further multivariable modelling was performed with anti-
hypertensive treatment (HTT), current SBP, BMI, T2DM, smoking
status, and physical activity status as covariables. Regression diagnostics
were performed, including checks of linearity by examination of residuals
and by testing for model improvement on addition of a quadratic term.
To investigate whether rate of change at a particular period of midlife
was more strongly associated with LVMI, we calculated the change
in SBP for the periods 36–43 years, 43–53 years, and 53–60/64 years
conditional on earlier SBP by modelling each SBP measure (from
43 years onwards) on the earlier measure(s) for each sex and saving
the residuals. These residuals reflect mean rate of change in SBP and
can be interpreted as the change in SBP above or below that expected
on average, given earlier SBP.15 The residuals were standardized to
allow a comparison of the relative strength of associations between
periods. We subsequently fitted regression models including all these
standardized changes with LVMI or relative wall thickness (RWT, a
measure of remodelling) as the outcome. The coefficients for each
period were compared against each other using Wald tests and models
were further adjusted for potential confounders. Relationships with
LVH were analysed using multivariable logistic regression. Sensitivity
analyses were carried out to assess whether the associations with BP
remained unchanged if those on HTT or those who were hypertensive
(SBP. ¼ 140 mmHg and/or DBP . ¼ 90 mmHg) were excluded.
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Figure1 (A) Predicted left ventricular mass index at 60–64 yearsby systolic blood pressure at 53 years (red) and by systolic blood pressure at 60–
64 years (blue) plotted separately for men and women and by antihypertensive treatment status. Vertical lines represent mean systolic blood pres-
sure in the National Survey of Health and Development sample; solid line for men and dashed line for women. (B) Predicted left ventricular mass
index at 60–64 years by standard deviation change in systolic blood pressure between 43 and 53 years (magenta) and between 53 and 60–64 years
(green) plotted separately for men (solid) and women (dashed), for individuals with an average conditional change in the other periods. Vertical lines
represent mean systolic blood pressure change.
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Results
Participant characteristics are shown inTable 1. Twenty-four percent of
the sample was receiving antihypertensive medication (details of the
class of antihypertensive agent used are shown in Supplementary
material online, Table S1); 5% of the sample had T2DM; and a normal
LV geometry was seen in 43%. Compared with those who attended
for echocardiography, those who had home visits had higher BP
(138.4/79.3 vs. 135.6/77.3 mmHg), BMI (28.7 vs. 27.6), and a greater
prevalence of T2DM (11 vs. 5%) and hypertension (32 vs. 24%).
Associations between left ventricular
measures and blood pressure at various
ages
Associations between BP and LV outcomes were qualitatively similar
for all measures of BP (SBP, DBP, PP, and MAP), so results for SBP are
shown below and associations for DBP, PP, and MAP are provided in
Supplementary material online, Table S2–S4.
Higher SBP from 36 years onwards was associated with higher
LVMI at 60–64 years (Table 2). Associations remained essentially
unchanged after adjustment for HTT (Model 2). Systolic blood pres-
sure at 53 years remained independently associated with LVMI with
only marginal attenuation in an additional model that was adjusted
for SBP at 60–64 years (Model 3), but associations with SBP at 36
years and particularly with SBP at 43 years were weakened. The rela-
tionships between LVMI and BP at 53 years and LVMI and HTT at 53
years remained after further adjustment for BMI, presence of T2DM,
smoking and physical activity status at 60–64 years. A 10 mmHg
higher SBP at 53 years was associated with a 2.2 g/m2 higher LVMI
after adjustment for age, sex, CRF attended, HTT, and SBP at
60–64 years.
These associations remained when those with hypertension or on
HTT were excluded from analyses (Supplementary material online,
Table S5 and S6, respectively), although associations with earlier
measures of SBP were slightly reduced.
Relationships between BP (both SBPand DBP) andRWT showed a
similar pattern to those between BPand LVMI. Therewas evidence of
associations of BP from 43 years onwards with RWT which were
independent of BP at 60–64 years (Table 3; Supplementary material
online, Table S7).
LVH was also associated with BP from 36 years onwards, although
only weakly with BP at 43 years. The association at 53 years was inde-
pendent of BP at 60–64 years and was unaffected by adjustment for
other covariables (for SBP: odds ratio ¼ 1.25, 95% CI ¼ 1.07, 1.45
per 1 SD increase in SBP at 53 years adjusted for age, sex, CRF
attended, HTT, SBP at 60–64 years, T2DM, BMI, smoking, and
physical activity).
Associations between left ventricular
measures and antihypertensive treatment
at various ages
Individuals on HTT from 43 years onwards had a higher mean LVMI
than those who were not on treatment (Table 2); this difference per-
sisted after adjusting for SBP at 60–64 years and other covariables.
For example, individuals receiving HTT at 60–64 years had an
LVMI that was 11.2 g/m2 greater than those not receiving treatment.
Further adjustment for SBP at 60–64 years and other covariables
reduced the associations slightly.
We investigated the possibility that the relationship between LVMI
and HTT could be explained by people receiving treatment at 60–64
years including a disproportionate number of individuals with high BP
at 53 years. However, adjustment for SBP at 53 years only slightly
attenuated the effect of HTT on LVMI from 11.2 (95% CI: 7.9, 14.4)
g/m2–7.9 (95% CI: 4.3, 11.4) g/m2. Adjustment for SBP at younger
ages had negligible effects.
Evidence for a rate-sensitive period
in midlife
Faster increases in SBPbetween43–53and53–60/64yearswere sig-
nificantly related to greater LVMI (Figure 1), whereas increased rate of
change in SBP between 36 and 43 years was only weakly related to
LVMI. The relationship between rate of change in SBP between 43
and 53 years was significantly stronger than the other two intervals
(P ¼ 0.002 for both). After adjustment for HTT, T2DM, BMI,
smoking status, and physical activity (Table 4), the associations with
change in the latest two periods remained, although the association
between change in SBP between 43 and 53 years was somewhat wea-
kened. Estimates were essentially unaltered when further adjusted
for prior measuresof BMI or changes in BMI (Supplementary material
online, Table S8).
Analyses with left ventricular mass indexed
to height1.7 or height2.7
All analyseswere repeatedwithLVMindexed toheight1.7 andheight2.7.
Associations were qualitatively similar to those for LVM indexed to
BSA. The associations between SBP and DBP at various ages and alter-
natively indexed LVM are presented in Supplementary material online,
Table S9 and S10.
Discussion
Elevated BP from early midlife predicts higher LVMI, LVH, and LV
remodelling in older men and women independent of current BP.
We identified 43–53 years as a potential sensitive period when
rapid rises in SBP may be particularly detrimental for the develop-
ment of adverse cardiac structure. We also found that people receiv-
ing HTT had higher LVMI, even after accounting for current BP; only
some of this effect could be accounted for by prior higher BP.
A few previous studies have investigated the relationship between
antecedent high BP in earlier life on subsequent LVM. Urbina et al.16
reported a significant positive correlation between SBP at baseline in
young women but not young men (average age 13 years) and LVM
measured 4 years later. Toprak et al.17 failed to find a significant
relationship between SBP measured at 13 years and LV geometry
in adulthood, although high DBP in childhood was associated with
subsequent concentric LVH. Dekkers et al.18 found that PP and SBP
measured in early adolescence correlated with LVM measured in
African American and European American youths 10 years later;
and Ridderstrale et al.19 reported that high BP in a selection of hyper-
tensive male military recruits and controls aged 20 was predictive
of higherLVM20years later.Twoother studieshave reported thatBP
in middle age was positively associated with LVM measured two
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Table 1 Characteristics of study participants having at least one echocardiographic measure of interest recorded (n5 1480)
Variable N men/women Value (combined) Value [men (n 5 701)] Value [women (n 5 779)]
Age at echo (years) 701/779 63.3 (1.1) 63.2 (1.1) 63.3 (1.1)
Body mass index (kg/m2) 701/779 27.5 (4.6) 27.7 (4.0) 27.4 (5.1)
Left ventricular internal diameter in diastole (cm) 701/779 4.82 (0.6) 5.05 (0.6) 4.61 (0.5)
Interventricular septal thickness in diastole (cm) 701/779 1.1 (0.2) 1.1 (0.2) 1.0 (0.2)
Left ventricular posterior wall thickness in diastole (cm) 701/779 1.0 (0.2) 1.0 (0.2) 0.9 (0.2)
Left ventricular mass (g) 701/779 181.3 (59.3) 209.1 (60.4) 156.04 (45.7)
Left ventricular mass indexed to BSA (g/m2) 701/779 95.7 (26.6) 104.0 (28.0) 88.1 (23.0)
Left ventricular mass indexed to height1.7 (g/m1.7) 701/779 74.3 (22.5) 80.6 (23.5) 68.3 (20.0)
Left ventricular mass indexed to height2.7 (g/m2.7) 701/779 44.2 (13.2) 46.1 (13.7) 42.4 (12.6)
Relative wall thickness 701/777 0.42 (0.09) 0.42 (0.09) 0.41 (0.08)
Ejection fraction (%) 700/776 68.7 (9.7) 67.2 (10.1) 69.9 (9.2)
Left ventricular remodelling subtype (normal/concentric remodelling/
concentric hypertrophy/eccentric hypertrophy), n (%)
701/779 632 (43)/396 (27)/
240 (16)/212 (14)
287 (41)/202 (29)/
113 (16)/99 (14)
345 (44)/194 (25)/
127 (16)/113 (15)
Systolic blood pressure at 60–64 years (mmHg) 701/777 135.7 (17.9) 139.0 (17.7) 132.8 (17.7)
Systolic blood pressure at 53 years (mmHg) 659/739 134.1 (19.1) 137.8 (18.9) 130.7 (18.7)
Systolic blood pressure at 43 years (mmHg) 655/730 121.5 (14.5) 123.0 (14.3) 120.1 (14.6)
Systolic blood pressure at 36 years (mmHg) 633/706 118.3 (14.0) 121.3 (14.2) 115.6 (13.4)
Diastolic blood pressure at 60–64 years (mmHg) 701/777 77.4 (9.7) 79.0 (9.8) 75.9 (9.3)
Diastolic blood pressure at 53 years (mmHg) 659/739 83.4 (11.9) 86.2 (11.9) 80.9 (11.3)
Diastolic blood pressure at 43 years (mmHg) 655/730 78.5 (11.3) 80.9 (11.2) 76.3 (10.9)
Diastolic blood pressure at 36 years (mmHg) 632/706 76.0 (11.7) 77.8 (11.7) 74.4 (11.4)
Heart rate (bpm) 701/777 68.5 (11.8) 67.2 (12.5) 69.7 (11.0)
Total cholesterol (mmol/L) 657/729 5.7 (1.2) 5.4 (1.1) 6.0 (1.2)
High-density lipoprotein cholesterol (mmol/L) 657/729 1.6 (0.4) 1.4 (0.3) 1.8 (0.4)
Fasting triglycerides (mmol/L)a 657/729 1.1 (0.8) 1.2 (0.9) 1.0 (0.7)
Fasting glucose (mmol/L) 667/740 5.8 (1.2) 6.0 (1.2) 5.6 (1.2)
Haemoglobin A1C (%) 656/731 5.8 (0.7) 5.8 (0.7) 5.8 (0.6)
Antihypertensive medication, n (%) on antihypertensive
medication with controlled BP (,140/90 mm Hg), n (%)
620/712 315 (24) 159 (26) 156 (22)
169 (53)b 79 (50) 90 (58)b
T2DM, n (%) 635/722 73 (5) 37 (6) 36 (5)
Data are mean (SD).
aMedian (interquartile range) for skewed variables.
bOne individual receiving antihypertensive medication was missing a valid measurement of blood pressure.
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decades later.20,21 The majority of these studies did not examine
whether the effect of antecedent BP was independent of current
BP and therefore the possibility that these observations were
simply a consequence of a high correlation between antecedent
and current BP (i.e. tracking) could not be excluded. However, a lon-
gitudinal analysis of the Framingham offspring study22 reported that
BP in adulthood (mean age 45 years) correlated with the trajectory
of LVM over a subsequent 16 years period.
Our findings based on multiple longitudinal measurements of BP
extend these earlier studies and show that the effects of antecedent
BP in adulthoodarenotwhollyattributable to trackingofBP.Notably,
BP at 53 years was more strongly related to LVMI and RWT than BPat
60–64 years and remained significant in a mutually adjusted model
suggesting that midlife BP is more influential for LV structure than
BP at age 60–64. After adjustment for current BP a 1 SD increase
in BP at age 53 years was associated with a 4.2 g/m2 higher LVMI,
and a 1 SD higher BP at age 53 years was associated with a 25%
increased odds of LVH at age 60–64 years. These associations
persisted even after multivariable adjustment for other risk factors
including BP at age 60–64 years. We further show that a more
rapid BP rise between 43–53 years is the strongest correlate of ele-
vated LVMI, with a 1 SD higher rate of rise in BP in this period being
associated with a 5.1 g/m2 greater LVMI. The increases in LVM asso-
ciated with antecedent BP and rate of rise of BP are likely to have
prognostic implications: an 5 g/m2 higher LVMI (0.2 SD of
LVMI) can be predicted to correspond to a 7–20% increase in
CVD morbidity and mortality on the basis of previous outcome
studies.23,24 The importance of BP at 53 years as a predictor of
LVMImay reflect the relatively rapid acceleration inBPwhich typically
precedes this age.25 We analysed rate of change in BP over a 28-year
period and divided it into temporal segments to establish if there was
a ‘sensitive’ period when exposure to elevated BP had a particularly
strong influence.15 Our data suggest that the 5th decade of life
(40–50 years) may be such a period. This is consistent with previ-
ous data relating lifetime risk of CVD to BP and BP change in middle
age.5 It is also interesting to note that both elevated BP and an exag-
gerated rise in midlife have also previously been reported to be risk
factors for dementia two to three decades later, regardless of subse-
quent BP.26,27
Our finding that people with treated hypertension had higher
LVMI, even after adjustment for current BP, is in keeping with a pre-
vious study showing that LVMI and prevalence of LVH was greater in
individuals with well-controlled BP than in normotensive indivi-
duals.28 This led the authors to suggest that effective treatment of
hypertension may not achieve complete reversal of cardiac target
organ damage. The question of the part played by regression of
LVM in risk reversal by HTT is debated.29 However, we speculate
that elevated BP in midlife causes a ‘legacy’ of cardiac target organ
damage including interstitial and perivascular fibrosis that may be
difficult to reverse even if BP is subsequently well controlled with
medication.30 This provides an additional rationale for on-going
therapeutic efforts targeted at reversal of myocardial fibrosis.31
While elevated LVM predicts coronary events and cardiac failure,2
whether the failure to achieve normalization of LVM implies a subse-
quent excess of CVD and heart failure remains to be established.
Planned future follow-ups of the British MRC NSHD cohort will
provide important information on this question.
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Current hypertension guidelines do not take into account ante-
cedent BP or changes in BP when initiating therapy.32,33 Our data
suggest that this may miss an opportunity to prevent cardiac target
organ damage and its sequelae (e.g. heart failure) in later life. Recent
randomized clinical trials have examined the short-term effect of
antihypertensive agents in preventing development of hypertension
in high-risk individuals with conflicting results.34,35 However, we are
unaware of any studies exploring the possible longer-term benefits
of BP lowering in individuals with pre-hypertension or an elevated
rate of rise in BP in midlife. We suggest this may be a fruitful area of
future clinical research.
Strength and limitations
Participants in the MRC NSHD have previously been found to be rep-
resentative of native-born adults living in England, Scotland, and
Wales at the time of data collection.9 Hence, our findings are likely
to be generalizable to the native-born British population. The
repeated measurements of BP in our study, the longest running
birth cohort in Britain, allowed us a rare opportunity to carry out a
longitudinal analysis investigating importance of BP and rate of
change in BP over different periods of adulthood. Missing data are
inevitable in studies as long running as the MRC NSHD;14 however,
response and attendance rates were acceptable. Compared with
study members who had echocardiography, those who had examina-
tions at home had higher BP and were less healthy, consistent with
previous work.36 Exclusion of this less healthy group from our ana-
lyses may have resulted in an underestimation of the strength of asso-
ciations between BP and LV structure. Blood pressure was not
measured in the NSHD prior to 36 years, and hence we were
unable to assess whether there are important periods in earlier life
when BP may influence cardiac structure. We are also limited to iden-
tifying three potential sensitive periods of10 years duration; hence,
we may have underestimated the extent of BP change and/or the
importance of more rapid rises in BP over shorter-time periods than
the 10 years sampling intervals. The lack of 24 h ambulatory mea-
surements of BP in this cohort also precludes us from examining
whether short-term variability or diurnal variation in BP contributes
to the associations seen. While we examined a range of potential con-
founders, unmeasured confounders, or mediators that influence
cardiac hypertrophy (e.g. renin–angiotensin system activity, sympa-
thetic nervous system activity, abnormalities of lipid metabolism,
inflammation, etc.) may have contributed to the associations
observed.29 Echocardiography was only carried out in the most
recent round of data collection and hence the possibility of reverse
causality, namely that increased LVM in early-life results in raised BP
and increased rate of rise in midlife BP cannot be excluded.
However, a previous study by Zureik et al.37 demonstrated that
change inBPprecededchange inLVMI, arguing against this explanation.
Conclusions
Higher BP in midlife and, in particular, a rapid rate of BP increase in the
5th decade is associated with higher LVM and LV remodelling in later
life; this association is independent of current BP. People with treated
hypertension have higher LVMI than untreated individuals, even
when accounting for their higher BP. Our findings emphasize the
importance of midlife BP as risk factor for future CVD.
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